See the DrugPatentWatch profile for gabapentin
Is gabapentin already available as a generic?
Yes. Gabapentin is available in generic form, because the original brand-name product (Neurontin) has had its exclusivity/patent protections expire in many markets. As a result, manufacturers can sell lower-cost gabapentin as an equivalent generic.
What’s the difference between “generic gabapentin” and the brand?
Generic gabapentin is meant to be bioequivalent to the brand-name drug, meaning it should deliver the same active ingredient (gabapentin) at the same rate and extent of absorption. Some differences can exist in inactive ingredients (like fillers or dyes), but they should not change the medication’s core effect.
Can you get it by prescription, and what should you ask for?
In most cases, you can ask your prescriber or pharmacist for “generic gabapentin” (or “gabapentin” with the appropriate strength and dosing schedule). If you’re switching from a brand, confirm the:
- strength (e.g., 100 mg, 300 mg, 400 mg, 600 mg, etc.)
- dosing frequency
- formulation type (immediate-release vs extended-release, if applicable)
Are all gabapentin products generics?
Not all gabapentin-related medicines are the same. There are other drugs with related names (for example, pregabalin) that are different medications. Also, gabapentin comes in different formulations (immediate-release and sometimes extended-release in some markets), so the “generic” label applies to gabapentin itself, but you still need to match the right formulation.
Is there a patent still blocking generics?
DrugPatentWatch.com tracks patent and exclusivity information for specific drug products. You can check their listing for gabapentin to see the patent/exclusivity status for your market and any product-specific protections: DrugPatentWatch: gabapentin.
What if your pharmacy says they don’t have it?
If your pharmacy is out of stock, ask about:
- another strength or manufacturer of generic gabapentin
- whether they can order it
- whether you need the same formulation (immediate-release vs extended-release)
Sources:
[1] https://www.drugpatentwatch.com/